PortfoliosLab logoPortfoliosLab logo
ORCL vs. NVO
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ORCL vs. NVO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Oracle Corporation (ORCL) and Novo Nordisk A/S (NVO). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ORCL achieves a -37.12% return, which is significantly lower than NVO's 0.91% return. Over the past 10 years, ORCL has outperformed NVO with an annualized return of 13.12%, while NVO has yielded a comparatively lower 8.18% annualized return.


ORCL

1D
-3.98%
1M
-33.91%
6M
-36.04%
YTD
-37.12%
1Y
-49.98%
3Y*
2.24%
5Y*
7.68%
10Y*
13.12%
ALL TIME*
21.29%

NVO

1D
-1.41%
1M
14.86%
6M
-17.63%
YTD
0.91%
1Y
-19.26%
3Y*
-13.51%
5Y*
4.43%
10Y*
8.18%
ALL TIME*
14.52%
*Multi-year figures are annualized to reflect compound growth (CAGR)

ORCL vs. NVO - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
ORCL
Oracle Corporation
-37.12%18.13%59.99%30.94%-4.65%36.89%24.25%19.34%-2.97%24.94%
NVO
Novo Nordisk A/S
0.91%-39.22%-15.93%54.84%22.66%63.52%23.33%28.70%-12.98%52.92%

Correlation

The correlation between ORCL and NVO is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.19

Correlation (3Y)
Calculated over the trailing 3-year period

0.25

Correlation (5Y)
Calculated over the trailing 5-year period

0.27

Correlation (10Y)
Calculated over the trailing 10-year period

0.26

Correlation (All Time)
Calculated using the full available price history since Mar 12, 1986

0.19

Fundamentals

Market Cap

ORCL:

$349.60B

NVO:

$220.46B

EPS

ORCL:

$5.86

NVO:

DKK 27.42

PE Ratio

ORCL:

20.71

NVO:

11.83

PEG Ratio

ORCL:

0.85

NVO:

0.51

PS Ratio

ORCL:

5.25

NVO:

4.40

PB Ratio

ORCL:

8.22

NVO:

7.11

Total Revenue (TTM)

ORCL:

$67.36B

NVO:

DKK 327.80B

Gross Profit (TTM)

ORCL:

$79.58B

NVO:

DKK 268.30B

EBITDA (TTM)

ORCL:

$6.20B

NVO:

DKK 181.54B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ORCL vs. NVO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ORCL
ORCL Risk / Return Rank: 1212
Overall Rank
ORCL Sharpe Ratio Rank: 1212
Sharpe Ratio Rank
ORCL Sortino Ratio Rank: 1010
Sortino Ratio Rank
ORCL Omega Ratio Rank: 1313
Omega Ratio Rank
ORCL Calmar Ratio Rank: 1313
Calmar Ratio Rank
ORCL Martin Ratio Rank: 1313
Martin Ratio Rank

NVO
NVO Risk / Return Rank: 3030
Overall Rank
NVO Sharpe Ratio Rank: 2929
Sharpe Ratio Rank
NVO Sortino Ratio Rank: 2929
Sortino Ratio Rank
NVO Omega Ratio Rank: 2929
Omega Ratio Rank
NVO Calmar Ratio Rank: 3232
Calmar Ratio Rank
NVO Martin Ratio Rank: 3333
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ORCL vs. NVO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Oracle Corporation (ORCL) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


ORCLNVODifference
Sharpe ratioReturn per unit of total volatility

-0.39

Sortino ratioReturn per unit of downside risk

-1.04

Omega ratioGain probability vs. loss probability

0.87

0.97

-0.11

Calmar ratioReturn relative to maximum drawdown

-0.80

-0.39

-0.41

Martin ratioReturn relative to average drawdown

-1.28

-0.61

-0.67

ORCL vs. NVO - Sharpe Ratio Comparison

The current ORCL Sharpe Ratio is -0.77, which is lower than the NVO Sharpe Ratio of -0.37. The chart below compares the historical Sharpe Ratios of ORCL and NVO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

ORCL vs. NVO - Drawdown Comparison

The maximum ORCL drawdown since its inception was -84.19%, which is greater than NVO's maximum drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for ORCL and NVO.


Loading charts...

Drawdown Indicators


ORCLNVODifference

Max Drawdown

Largest peak-to-trough decline

-84.19%

-74.70%

-9.49%

Max Drawdown (1Y)

Largest decline over 1 year

-62.61%

-49.17%

-13.44%

Max Drawdown (3Y)

Largest decline over 3 years

-62.61%

-74.70%

+12.09%

Max Drawdown (5Y)

Largest decline over 5 years

-62.61%

-74.70%

+12.09%

Max Drawdown (10Y)

Largest decline over 10 years

-62.61%

-74.70%

+12.09%

Current Drawdown

Current decline from peak

-62.61%

-63.95%

+1.34%

Average Drawdown

Average peak-to-trough decline

-29.16%

-17.89%

-11.27%

Ulcer Index

Depth and duration of drawdowns from previous peaks

39.16%

31.75%

+7.41%

Volatility

ORCL vs. NVO - Volatility Comparison

Oracle Corporation (ORCL) has a higher volatility of 13.67% compared to Novo Nordisk A/S (NVO) at 9.48%. This indicates that ORCL's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ORCLNVODifference

Volatility (1M)

Calculated over the trailing 1-month period

13.67%

9.48%

+4.19%

Volatility (6M)

Calculated over the trailing 6-month period

42.95%

37.43%

+5.52%

Volatility (1Y)

Calculated over the trailing 1-year period

65.37%

51.79%

+13.58%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

42.65%

38.58%

+4.07%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

35.47%

32.63%

+2.84%

Dividends

ORCL vs. NVO - Dividend Comparison

ORCL's dividend yield for the trailing twelve months is around 1.65%, less than NVO's 3.63% yield.


PositionTTM20252024202320222021202020192018201720162015
NVO
Novo Nordisk A/S
3.63%3.31%1.68%1.00%1.20%1.35%1.87%2.14%1.45%1.52%2.87%0.92%
ORCL
Oracle Corporation
1.65%0.97%0.96%1.44%1.57%1.38%1.48%1.72%1.68%1.52%1.56%1.56%

Financials

ORCL vs. NVO - Financials Comparison

This section allows you to compare key financial metrics between Oracle Corporation and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00B40.00B60.00B80.00B100.00B20222023202420252026
19.18B
96.82B
(ORCL) Total Revenue
(NVO) Total Revenue
Please note, different currencies. ORCL values in USD, NVO values in DKK

Frequently Asked Questions


ORCL and NVO have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ORCL has higher volatility (13.67%) compared to NVO (9.48%). In terms of maximum drawdown, ORCL dropped -84.19% vs NVO's -74.70%.

NVO currently has the higher Sharpe Ratio (-0.37 vs -0.77), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ORCL and NVO

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer